

PROVIDERALERT



To: AmeriHealth Caritas Louisiana Providers

Date: October 9, 2020

Subject: Vitamin D Screening Policy

Summary: CCP.1414.04 Vitamin D screening

Content

AmeriHealth Caritas Louisiana would like to make you aware of the attached policy that has been approved by the Louisiana Department of Health in accordance with La. R.S. 46:460.54 and will become effective 12/01/2020.

Questions:

Thank you for your continued support and commitment to the care of our members. If you have questions about this communication, please contact AmeriHealth Caritas Louisiana's Provider Services department at 1-888-922-0007 or your [Provider Network Management Account Executive](#).

Missed an alert?

You can always find a complete listing of provider alerts on the [Newsletters and Updates](#) page of our website.

Where can I find more information on COVID-19?

AmeriHealth Caritas Louisiana has updated its website to streamline communications and important notifications about COVID-19. Please visit <http://amerihealthcaritasla.com/covid-19> for update-to-date information for both providers and members, including frequently asked questions, cancellations and postponements, and important provider alerts from AmeriHealth Caritas Louisiana and the Louisiana Department of Health.

Vitamin D screening

Clinical Policy ID: CCP.1414.04

Recent review date: 5/2020

Next review date: 9/2021

Policy contains: Vitamin D assay testing, Vitamin D screening, Osteopenia, Bone Density; Vitamin D supplementation.

AmeriHealth Caritas Louisiana has developed clinical policies to assist with making coverage determinations. AmeriHealth Caritas Louisiana's clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peer-reviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any state- or plan-specific definition of "medically necessary," and the specific facts of the particular situation are considered by AmeriHealth Caritas Louisiana when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. AmeriHealth Caritas Louisiana's clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. AmeriHealth Caritas Louisiana's clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, AmeriHealth Caritas Louisiana will update its clinical policies as necessary. AmeriHealth Caritas Louisiana's clinical policies are not guarantees of payment.

Coverage policy

Vitamin D screening (CPT 82306 and 82652) is clinically proven and therefore medically necessary for AmeriHealth Caritas Louisiana members who exhibit signs or symptom of vitamin D deficiency (CMS 2019a; CMS 2019b; Holick 2011) and meet the billing and coding requirements outlined by the Centers for Medicare and Medicaid Services Local Coverage Determination Vitamin D Assay testing (A57736).

1. CPT code 82306 must accompany medical necessity for one or more ICD-10-CM group one codes listed in CMS LCD A57736
2. CPT code 82652 must accompany medical necessity for one or more ICD-10-CM group two codes listed in CMS LCD A57736 (CMS 2019a).

Limitations

- Limit one screening per year, unless the member has been shown to be vitamin D deficient, further testing (limit four per year) may be medically necessary to ensure adequate replacement has been accomplished.
- Screening for vitamin D deficiency is investigational, and therefore not medically necessary in asymptomatic adults age 18 years and older (U.S. Preventive Services Task Force, 2014).
- Testing may not be used for routine or other screening (Centers for Medicare & Medicaid Services, 2019a).

Alternative covered services

No alternative covered services were identified during the writing of this policy.

Background

Vitamin D is a fat-soluble vitamin that is ingested through foods, sun exposure, and supplements. It promotes calcium absorption and normal growth of bone. Without adequate levels of vitamin D, bone can become thin, brittle, or misshapen. In addition, the vitamin helps modulate cell growth, enhance neuromuscular and immune function, and reduce inflammation. Vitamin D deficiency can lead to rickets in children and osteomalacia/osteoporosis in adults.

The Institute of Medicine considers any human with levels of less than 30 nanomoles per liter serum 25-hydroxyvitamin D to have vitamin D deficiency. The Institute also recommends daily intakes of vitamin D, which vary by age (persons over age 70 require 800 international units a day, while infants under age 1 require just 400; the remainder between ages 1 and 70 years require 600). Foods with the most vitamin D include cod liver oil, certain fishes (sockeye salmon, swordfish, tuna), orange juice, milk, and yogurt (National Institutes of Health, 2018).

Estimates of vitamin D intake from food and supplements have been calculated to range (by age group) from 204 to 288 international units per day for males and 144 to 276 for females. A total of 37% of Americans use dietary supplements containing vitamin D.

The prevalence of vitamin D deficiency has been a concern among American public health officials for over a decade. The National Center for Environmental Health and the National Center for Health Statistics sampled Americans 12 years and older (n = 51,146) for 25-hydroxyvitamin D₂ and 25-hydroxyvitamin D₃ — a measure of vitamins D₂ and D₃ combined — with those < 40 nanomoles per liter considered to have low levels. From 1988-1994 to 2005-2006, the percentage of deficient Americans increased. From 2005-2006 to 2009-2010, analysts observed a decrease due to the increased use of vitamin D supplements by persons over 40.

The current (2009-2010) rate of Americans over age 12 who are vitamin D deficient is 15%. Rates vary by race and ethnicity (non-Hispanic whites = 6.6%, Mexican-Americans = 23%, and non-Hispanic blacks = 46%) (Schleicher, 2016).

Vitamin D deficiency is also common among children, especially those who are overweight. The prevalence of the deficiency, defined as < 50 nanomoles per liter, for U.S. children ages 6 to 18 years was 21% (healthy weight), 29% (overweight), 34% (obese), and 49% (severely obese). Among severely obese white, Latino, and African American children, the proportions were 27%, 52%, and 87%, respectively (Turer, 2013).

Vitamin D testing has increased greatly in recent years. From 2000 to 2014, the proportion of Americans over age 70 taking a vitamin D test rose from 4/1,000 to 4/10 — a 100-fold increase (Rooney, 2017). Increases such as this have prompted a discussion about when this test is medically necessary.

Medicare paid \$224 million for vitamin D assay testing in 2014, a sharp increase from just a decade earlier (Rockwell, 2014). An estimated 7.5 million outpatient visits occurred in the U.S. in the four-year period 2007-2010 with a diagnosis of vitamin D deficiency (Huang, 2014), while an estimated 10% to 16% of Medicare patients and 5% to 10% of commercially insured patients were tested for vitamin D levels in the two-year period 2009-2011 (Colla, 2017).

Findings

The American Association of Clinical Endocrinologists guideline for Vitamin D screening, which it states is similar to those of the Endocrine Society, Mayo Clinic, and U.S. Preventive Services Task Force, recommends screening for individuals with risk factors, listed in the coverage section of this policy (American Association of Clinical Endocrinologists, 2019).

Another guideline, issued by the U.S. Preventive Services Task Force, recommends against universal screening for vitamin D deficiency. The task force found no references that assessed benefits or harms of screening for the deficiency in asymptomatic adults. The Task Force noted commonly reported risk factors for low vitamin D levels, including decreased dietary vitamin D intake, absorption, or synthesis due to decreased sun exposure or darker skin pigmentation; older age; inflammatory bowel disease, malabsorptive conditions, or history of gastric bypass; being homebound or institutionalized; routinely wearing clothing that prevents sun exposure on most of the skin; and living at high latitudes.

Finally, the group found adequate evidence that treatment of asymptomatic vitamin D deficiency has no benefit on cancer, type 2 diabetes mellitus, risk for death in community-dwelling adults, risk for fractures in persons not selected on the basis of being at high risk for fractures; and inadequate evidence on the benefit of treatment of asymptomatic vitamin D deficiency on other outcomes, including psychosocial and physical functioning (U.S. Preventive Services Task Force, 2014).

A Centers for Medicare & Medicaid Services Local Coverage Determination, in effect starting November 14, 2019, lists the conditions for which serum 25-hydroxyvitamin testing is indicated. See the Local Coverage Determination citation later in this policy, and the list of conditions for testing in the coverage section (Centers for Medicare & Medicaid Services, 2019).

Numerous systematic reviews and meta-analyses, plus other large-scale studies, have analyzed associations between vitamin D supplements and health outcomes. Below are results of these studies published in 2018. Results are mixed; some show improved outcomes, some do not, and some include both.

- Active tuberculosis (n = 1,787). Supplements could be used in conjunction with standard treatment based on significantly higher sputum smear and culture proportions, but did not impact adverse events and mortality (Wu, 2018).
- Cancer (all), 30 trials (n = 30,808). No evidence that supplementation was associated with a decrease in cancer-related incidence or mortality was found (Goulao, 2018).
- Cancer (all). A systematic review of 52 trials (n = 75,454) revealed a significant reduction between reduced risk of cancer death (RR = 0.84), but non-significant reductions for all causes (RR = 0.98) and cardiovascular disorders (RR = 0.98), and all non-cancer, non-cardiovascular causes (RR = 1.05) (Zhang, 2019).
- Cancer (colorectal), 11 trials (n = 7,718). Increased serum 25-hydroxyvitamin D concentrations improved survival in patients with colorectal cancer, and recommended supplementation be the subject of randomized trials (Maalmi, 2018).
- Cancer (prostate), 22 trials. Men taking supplements had insignificantly lower prostate cancer mortality, but 19% had at least a 50% reduction in prostate-specific antigen, which was statistically significant (Shahvazi, 2018).
- Diabetes, 28 trials. Supplements given to non-diabetics showed no effects on fasting plasma glucose levels or insulin resistance. However, significant improvements were observed for patients with diabetes

for those with low body mass index or low serum 25-hydroxyvitamin D, and risk of type 2 diabetes mellitus was lower for pre-diabetic individuals (He, 2018).

- Diabetes, 20 trials (n = 2,703). Supplementation's effects on diabetes risk significantly improved. Vitamin D levels in short-term, high dose, non-obese, baseline vitamin D-deficient individuals, as well as reducing insulin resistance effectively (Li, 2018).
- Diabetes (type 2), 20 trials (n = 1,270). Supplements reduced levels of chronic low-grade inflammation, including C-reactive protein, tumor necrosis factor α , and erythrocyte sedimentation rate, in persons with diabetes, compared with placebo (Mousa, 2018).
- Diabetes (gestational), 16 trials. Six trials showed that supplements reduced the level of fasting plasma glucose and the incidence of gestational diabetes. Ten other trials found vitamin D supplements significantly reduced the level of fasting plasma glucose and fasting insulin and improved the homeostasis model of assessment-estimated insulin resistance (Yin, 2019).
- Diabetes (type 2), 19 trials (n = 1,374). Compared with the control group, persons with type 2 diabetes given short-term vitamin D supplements had a decline in hemoglobin A1c, insulin resistance, and insulin (Hu, 2019).
- Diabetes (diabetic nephropathy), 20 trials (n = 1,464). In patients with diabetic nephropathy, vitamin D supplements significantly reduced 24-hour urine protein ($P < .00001$); urinary albumin excretion rate ($P < .0001$); high sensitivity C reactive protein ($P < .00001$), and interleukin-6 ($P < .00001$), but had no impact on other indicators (Wang, 2019).
- Diabetes, 19 trials (n = 5,214) compared pregnant women taking levels of Vitamin D above versus below the recommended amount. While children of women taking higher amounts reduced the risk of gestational diabetes, but did not reduce rates of pre-eclampsia, preterm births, and low-weight births (Palacios, 2019).
- Fall risk, seven trials (n = 7,531). Results of this study on the risk of falls after taking supplements were mixed — some found higher risk, some found lower risk (Giurgis-Blake, 2018).
- Fall risk, 30 trials (n = 10,000). No evidence existed on the ability of supplements to reduce the risk of falls, but attributed this to data quality problems, stopping short of concluding vitamin D supplementation is ineffective (Tang, 2018).
- Falls (four trials, n = 4,512). A Cochrane review showed supplementation “probably” reduced falls among the institutionalized elderly (Cameron, 2018).
- Falls and fractures, 28 trials. Supplementation was highly effective in preventing falls and fractures (Poscia, 2018).
- Falls and fractures, 81 trials (n = 53,537). Supplements had no effect on total fractures (36 studies), hip fractures (20 studies), or falls (37 studies) (Bolland, 2018).
- Fractures and falls, numerous randomized trials. Supplements reduce fractures when administered with calcium in the institutionalized elderly; reduce acute respiratory tract infections if not given as bolus monthly or annual doses; and may reduce falls in those with the lowest serum 25-hydroxyvitamin D (25OHD) levels (Ebeling, 2018).
- Fracture incidence, two trials (n = 36,727). An insignificantly lower rate of fracture incidence resulted after supplementation with vitamin D and calcium. Vitamin D alone had no significant effect on all-cause mortality (Kahwati, 2018).
- Multiple sclerosis, 12 trials (n = 933). Supplements had no apparent effect on recurrence of relapse, worsening of disability, and magnetic resonance imaging lesions, while effects on health-related quality of life and fatigue are unclear (Jaquannath, 2018).
- Outcomes, critically ill persons (six trials, n = 695). Supplementation was associated with insignificant reductions in mortality ($P = .14$). In the oral-enteral group, insignificant reductions were found in mortality ($P = .12$) and average length of hospital stay ($P = .16$) (Langlois, 2018).

- Physical activity among elderly (36 trials, n = 4,947). Supplementation of adults age 55 and older resulted in a small positive effect on physical fitness (“get up and go”), and an increased effect when the daily dose was increased to 400 – 1,000 international units (Dewansingh, 2018).
- Pregnant women, 24 trials (n = 5,405). Supplements to pregnant women were associated with a (significant) 28% reduction in small for gestational age with no risk of fetal or neonatal mortality, along with higher birth weights (Bi, 2018).

A systematic review of 84 articles assessed the association between circulating 25-hydroxyvitamin D concentration and all-cause or cause-specific mortality in generally healthy populations. The vast majority of studies reported inverse associations between the two variables (higher vitamin D linked with lower mortality), up to a point. This association appeared to be non-linear, with progressively lower mortality with increasing 25(OH)D up to a point, beyond which there was no further decrease. There is moderate evidence of this inverse association with lung cancer mortality, and weak evidence of this inverse association of cardiovascular deaths (Heath, 2019).

Other systematic reviews and meta-analyses documented improvements in various biomarkers, and recommended that future trials of vitamin D supplementation be compared with morbidity and mortality outcomes.

A review of 175,830 persons over age 40 documented that a significantly lower proportion of outpatient visits among African-Americans were related to Vitamin D supplements ($P < .05$). Authors suggest more focused strategies targeting blacks are needed to maintain adequate vitamin D supplements (Lee, 2016).

References

On February 10, 2020, we searched PubMed and the databases of the Cochrane Library, the U.K. National Health Services Centre for Reviews and Dissemination, the Agency for Healthcare Research and Quality, and the Centers for Medicare & Medicaid Services. Search terms were Vitamin D assay testing, Vitamin D screening, and Vitamin D supplementation. We included the best available evidence according to established evidence hierarchies (typically systematic reviews, meta-analyses, and full economic analyses, where available) and professional guidelines based on such evidence and clinical expertise.

American Association of Clinical Endocrinologists. Bone Resource Center. Vitamin D deficiency. https://www.aace.com/sites/default/files/2019-02/Vitamin_D_Deficiency_formatted.pdf. Published 2019. Accessed February 14, 2020.

Bi WG, Nuyt AM, Weiler H, Leduc L, Santamaria C, Wei SQ. Association between Vitamin D supplementation during pregnancy and offspring growth, morbidity, and mortality: A systematic review and meta-analysis. *JAMA Pediatr.* 2018;172(7):635-645. Doi: 10.1001/jamapediatrics.2018.0302.

Bolland MJ, Grey A, Avenell A. Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. *Lancet Diabetes Endocrinol.* 2018;6(11):847-858. Doi: 10.1016/S2213-8587(18)30265-1.

Cameron ID, Dyer SM, Panagoda CE, et al. Interventions for preventing falls in older people in care facilities and hospitals. *Cochrane Database Syst Rev.* 2018;9:CD005465. Doi: 10.1002/14651858.CD005465.pub4.

Centers for Medicare & Medicaid Services. Vitamin D Assay Testing (Local Coverage Determination- A57736). 2019a. <https://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleId=57736&ver=3&DocID=A57736&SearchType=Advanced&bc=EAAAAAgAAAA&>. Latest revision effective November 14, 2019. Accessed July 9, 2020.

Centers for Medicare & Medicaid Services. Vitamin D Assay Testing (Local Coverage Determination L37535; also L33996, L34051, L36692, L34658). 2019b <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=37535&ver=16&SearchType=Advanced&CoverageSelection=Local&ArticleType=BC%7cSAD%7cRTC%7cReg&PolicyType=Both&s=All&Keyword=Vitamin+D+Assay&KeywordLookUp=Title&KeywordSearchType=Exact&kq=true&bc=EAAAABAAAA&>. Latest revision effective November 14, 2019. Accessed February 11, 2020.

Colla CH, Morden NE, Sequist TD, Mainor AJ, Li Z, Rosenthal MB. Payer type and low-value care: comparing choosing wisely services across commercial and Medicare populations. *Health Serv Res.* 2018;53(2):730-746. Doi: 10.1111/1475-6773.12665.

Dewansingh P, Melse-Boonstra A, Krijnen WP, van der Schans CP, Jager-Wittenaar H, van den Heuvel EGHM. Supplemental protein from dairy products increases body weight and vitamin D improves physical performance in older adults: a systematic review and meta-analysis. *Nutr Res.* 2018;49:1-22. Doi: 10.1016/j.nutres.2017.08.004.

Ebeling P, Adler R, Jones G, et al. Management of endocrine disease: Therapeutics of Vitamin D. *Eur J Endocrinol.* 2018;179(5):R239-R259. Doi: 10.1530/EJE-18-0151.

Giurgis-Blake JM, Michael YL, Perdue LA, Coppola EL, Beil TL. Interventions to prevent falls in older adults: updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA.* 2018 Apr 24;319(16):1705-1716. Doi: 10.1001/jama.2017.21962.

Goulao B, Stewart F, Ford JA, MacLennan G, Avenell A. Cancer and vitamin D supplementation: a systematic review and meta-analysis. *Am J Clin Nutr.* 2018;107(4):652-663. Doi: 10.1093/ajcn/nqx047.

He S, Yu S, Zhou Z, Wang C, Wu Y, Li W. Effect of vitamin D supplementation on fasting plasma glucose, insulin resistance and prevention of type 2 diabetes mellitus in non-diabetics: A systematic review and meta-analysis. 2018;8(5):475-484. Doi: 10.3892/br.2018.1074.

Heath AK, Kim IY, Hodge AM, English DR, Muller DC. Vitamin D status and mortality: A systematic review of observational studies. *Int J Environ Res Public Health.* 2019;16(3). pii: E383. Doi: 10.3390/ijerph16030383.

Hu Z, Chen J, Sun X, Wang L, Wang A. Efficacy of vitamin D supplementation on glycemic control in type 2 diabetes patients: A meta-analysis of interventional studies. 2019;98(14):e14970. Doi: 10.1097/MD.00000000000014970.

Huang KE, Milliron BJ, Davis SA, Feldman SR. Surge in US outpatient vitamin D deficiency diagnoses: National Ambulatory Medical Care Survey analysis. *South Med J.* 2014;107(4):214-7. Doi: 10.1097/SMJ.0000000000000085.

- Jaquannath VA, Filippini G, Di Pietrantonio C, et al. Vitamin D for the management of multiple sclerosis. *Cochrane Database Syst Rev*. 2018 Sep 24;9:CD008422. Doi: 10.1002/14651858.CD008422.pub3.
- Kahwati LC, Weber RP, Pan H, et al. Vitamin D, calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults: Evidence report and systematic review for the US Preventive Services Task Force. *JAMA*. 2018;319(15):1600-1612. Doi: 10.1001/jama.2017.21640.
- Langlois PL, Szewc C, D'Aragon F, Heyland DK, Manzanares W. Vitamin D supplementation in the critically ill: A systematic review and meta-analysis. *Clin Nutr*. 2018;37(4):1238-1246. Doi: 10.1016/j.clnu.2017.05.006.
- Lee S, Teschemaker AR, Daniel M, et al. Calcium and Vitamin D use among older adults in U.S.: Results from national survey. *J Nutr Health Aging*. 2016;20(3):300-305. Doi: 10.1007/s12603-015-0614-9.
- Li X, Liu Y, Zheng Y, Wang P, Zhang Y. The effect of Vitamin D supplementation on glycemic control in type 2 diabetes patients: A systematic review and meta-analysis. *Nutrients*. 2018;10(3). Doi: 10.3390/nu10030375.
- Maalmi H, Walter V, Jansen L, et al. Association between blood 25-hydroxyvitamin D levels and survival in colorectal cancer patients: An updated systematic review and meta-analysis. *Nutrients*. 2018;10(7). Doi: 10.3390/nu10070896.
- Mousa A, Naderpoor N, Teede H, Scragg R, de Courten B. Vitamin D supplementation for improvement of chronic low-grade inflammation in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. *Nutr Rev*. 2018;76(5):380-394. Doi: 10.1093/nutrit/nux077.
- National Institutes of Health, Office of Dietary Supplements. Vitamin D: Fact Sheet for Health Professionals. <https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/>. Last updated August 7, 2019. Accessed January 3, 2020.
- Palacios C, Trak-Fellermeier MA, Martinez RX, et al. Regimens of vitamin D supplementation for women during pregnancy. *Cochrane Database Syst Rev*. 2019 Oct 3;10:CD013446. Doi: 10.1002/14651858.CD013446.
- Paller CJ, Kanaan YM, Beyene DA, et al. Risk of prostate cancer in African-American men: Evidence of mixed effects of dietary quercetin by serum Vitamin D status. *Prostate*. 2015;75(13):1376-1383. Doi: 10.1002/pros.23018.
- Poscia A, Milovanovic S, La Milia DI, et al. Effectiveness of nutritional interventions addressed to elderly persons.: umbrella systematic review with meta-analysis. *Eur J Public Health*. 2018;28(2):275-283. Doi: 10.1093/eurpub/ckx199.
- Rockwell M, Kraak V, Hulver M, Epling J. Clinical management of low Vitamin D: A scoping review of physicians' practices. *Nutrients*. 2018 Apr; 10(4): 493. Doi: 10.3390/nu10040493.
- Rooney MR, Harnack L, Michos ED, Ogilvie RP, Sempos CT, Lutsey PL. Trends in use of high-dose vitamin D supplements exceeding 1000 or 4000 International Units daily, 1999–2014. *JAMA*. 2017;317(23):2448–2450. Doi: 10.1001/jama.2017.4392.

Schleicher RL, Sternberg MR, Lacher DA, et al. The vitamin D status of the US population from 1988 to 2010 using standardized serum concentrations of 25-hydroxyvitamin D shows recent modest increases. *Am J Clin Nutr*. 2016;104(2):454-461. Doi: 10.3945/ajcn.115.127985

Shahvazi S, Soltani S, Ahmadi SM, de Souza RJ, Salehi-Abargouei A. The effect of Vitamin D supplementation on prostate cancer: A systematic review and meta-analysis of clinical trials. *Horm Metab Res*. 2018 Dec 6. Doi: 10.1055/a-0774-8809.

Tang O, Juraschek SP, Appel LJ. Design features of randomized clinical trials of Vitamin D and falls: A systematic review. *Nutrients*. 2018;10(8). Doi: 10.3390/nu10080964.

Turer CB, Lin H, Flores G. Prevalence of vitamin D deficiency among overweight and obese US children. *Pediatrics*. 2013;131(1):e152-161. Doi: 10.1542/peds.2012-1711.

U.S. Preventive Services Task Force. Final recommendation statement. Vitamin D deficiency: screening. <https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/vitamin-d-deficiency-screening>. Published 2014, Accessed February 11, 2020.

Wang Y, Yang S, Zhou Q, Zhang H, Yi B. Effects of vitamin D supplementation on renal function, inflammation and glycemic control in patients with diabetic nephropathy: a systematic review and meta-analysis. *Kidney Blood Press Res*. 2019;44(1):72-87. Doi: 10.1159/000498838.

Wu HX, Xiong XF, Zhu M, Wei J, Zhuo KQ, Cheng DY. Effects of vitamin D supplementation on the outcomes of patients with pulmonary tuberculosis: a systematic review and meta-analysis. *BMC Pulm Med*. 2018;18(1):108. Doi: 10.1186/s12890-018-0677-6.

Yin W, Jin D, Yao M, Yu W, Zhu P. Effect of vitamin D supplementation on gestational diabetes mellitus: a Meta-analysis. *Wei Sheng Yan Jiu*. 2019;48(5):811-821. <https://www.ncbi.nlm.nih.gov/pubmed/31601326>. Accessed February 14, 2020.

Zhang Y, Fang F, Tang J, et al. Association between vitamin D supplementation and mortality: systematic review and meta-analysis. *BMJ*. 2019;366:l4673. Doi: 10.1136/bmj.l4673.

Policy updates

3/2019: initial review date and clinical policy effective date: 6/2019

5/2020: Eight references were added to, and two removed from the policy.

7/2020: LCD Vitamin D Assay (A57736) billing requirements added to coverage section.